Additionally, our findings establish the relevance of targeting TSP-1:CD47 axis in ovarian carcinoma, while positioning TAX2 as an innovative immunotherapeutic approach with demonstrated preclinical efficacy, either when considered as a monotherapy or in combination with immune checkpoint inhibition. The gene discussed is CD47; the disease is ovarian carcinoma.